StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
7091.T$1184.00-0.25%
Fair $1184.00+0.0%

7091.T

Living Platform,Ltd.

Healthcare / Medical Care FacilitiesTokyo

$1184.00

-3.00 (-0.25%)

Fairly Valued+0.0%Fair Value $1184.00Fund rank 17/100 · Data gapFallback financials|
SA 47/C
F-Score: 8/9
High Debt

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 35% · confianza 10%

FCF escenarios

weak_data · normalized FCF $68.0M · quality 13.7/100

Data gap 17/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 7/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

47/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Debt-to-Equity ratio is 3.19, above the 2.0 threshold
Thesis & Journal · 7091.TLocal privado en este navegador · Living Platform,Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$5.3B

P/E

13.4x

↓

EV/EBITDA

11.6x

↓

ROE

17.8%

↑

Gross Margin

10.1%

↓

Debt/Equity

3.19

↑
52-Week Range$1184
$858$1326

TradingView lightweight chart

7091.T price, volumen y niveles de valoración

Último $1,186Periodo +17.4%
Fair value: $1,184

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+18.2%

FCF CAGR

—

FCF margin

0.4%

FCF / Net income

0.19x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $19.20B · net income $365.6M · FCF $68.0M

2022-FY → 2025-FY

Gross margin

10.1%-1.4% pts

Operating margin

1.8%-2.4% pts

Net margin

1.9%-1.6% pts

FCF margin

0.4%+6.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$19.20B$19.20B$16.66B$13.69B$11.63B
Net Income$365.6M$365.6M$189.3M$91.7M$408.0M
EBITDA$885.7M$885.7M$791.1M$657.2M$1.02B
EPS81.7081.7042.3920.1590.13
Gross Margin10.1%10.1%8.7%9.3%11.5%
Operating Margin1.8%1.8%-0.5%-1.7%4.2%
Net Margin1.9%1.9%1.1%0.7%3.5%
Balance Sheet
Debt/Equity3.193.193.604.745.08
Current Ratio1.351.35———
Cash Flow
Free Cash Flow$68.0M$68.0M$878.3M$-770.8M$-726.7M
Returns
ROE17.8%17.8%11.4%6.2%30.3%
Valuation
P/E13.3613.3624.3074.4425.42
EV/EBITDA11.5711.5711.9518.1415.20
P/B2.582.582.774.647.70
Growth & Yield
Revenue Growth15.3%15.3%21.7%17.8%—
EPS Growth92.7%92.7%110.4%-77.6%—
Dividend Yield0.8%0.8%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

8.7%

razonable

EPS terminal req.

$105.06

Spread vs growth

84.0%

5Y implied EPS CAGR

9.2%

razonable

EPS terminal req.

$127.12

Spread vs growth

83.5%

10Y implied EPS CAGR

9.6%

razonable

EPS terminal req.

$204.73

Spread vs growth

83.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +20.2%

Total return

+20.2%

Start / end P/E

23.4x → 14.5x

EPS bridge

42.39 → 81.70

Residual

-35.3%

EPS growth+92.7%
Multiple rerating-38.1%
Dividend+0.8%
Residual / FX / buybacks / cross-term-35.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.